Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Common Equity (2020 - 2025)

BioAtla's Common Equity history spans 6 years, with the latest figure at $36.2 million for Q4 2025.

  • For Q4 2025, Common Equity rose 153.69% year-over-year to $36.2 million; the TTM value through Dec 2025 reached $36.2 million, up 153.69%, while the annual FY2025 figure was $36.2 million, 153.69% up from the prior year.
  • Common Equity reached $36.2 million in Q4 2025 per BCAB's latest filing, up from -$31.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $230.7 million in Q3 2021 to a low of -$31.2 million in Q3 2025.
  • Average Common Equity over 5 years is $102.3 million, with a median of $109.6 million recorded in 2023.
  • Peak YoY movement for Common Equity: surged 440.04% in 2021, then crashed 236.0% in 2025.
  • A 5-year view of Common Equity shows it stood at $210.8 million in 2021, then fell by 14.46% to $180.3 million in 2022, then tumbled by 60.81% to $70.7 million in 2023, then crashed by 79.82% to $14.3 million in 2024, then surged by 153.69% to $36.2 million in 2025.
  • Per Business Quant, the three most recent readings for BCAB's Common Equity are $36.2 million (Q4 2025), -$31.2 million (Q3 2025), and -$16.7 million (Q2 2025).